MetabolicFDA Approved

Dulaglutide (Trulicity)

Subcutaneous injection (weekly)

Overview

A long-acting GLP-1 receptor agonist consisting of a GLP-1 analog covalently linked to a modified human IgG4 Fc fragment via a peptide linker. This fusion protein design increases molecular size to reduce renal clearance and enables FcRn-mediated recycling, producing a half-life of approximately 5 days suitable for once-weekly dosing.

Mechanism of Action

Dulaglutide activates pancreatic GLP-1 receptors to enhance glucose-dependent insulin secretion and suppress glucagon..

Research Summary & Key Findings

AWARD trial program demonstrated superior HbA1c reduction vs. multiple comparators. REWIND trial (2019) showed 12% reduction in MACE in type 2 diabetes patients, including those without established cardiovascular disease. FDA-approved for type 2 diabetes (2014) and cardiovascular risk reduction.

Clinical Status

FDA Approved

Dulaglutide (Trulicity) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Subcutaneous injection (weekly)

Related Peptides in Metabolic

Find a Provider

Find a verified provider who offers Dulaglutide (Trulicity) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Dulaglutide (Trulicity).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.